Niki BioSolutions, Inc. Common Stock (NIKI)

• Market cap: $6.82M
• 1 day: -2.33%
• 5 days: -23.82%
• 1 month: -5.1%
• 3 months: -5.1%
• 6 months: -5.1%
• Year to date: -5.1%
• 1 year: -5.1%
• 5 years: -5.1%
• 10 years: -5.1%
• Sector: Technology
• Industry: Scientific & Technical Instruments

About: Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).

Employees: 2